These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37990182)

  • 21. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment.
    Kaldırım H; Yazgan S; Kırgız A; Atalay K; Savur F
    Curr Eye Res; 2019 Sep; 44(9):987-993. PubMed ID: 30983426
    [No Abstract]   [Full Text] [Related]  

  • 22. AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.
    Blanco-Garavito R; Jung C; Uzzan J; Quaranta-ElMaftouhi M; Coscas F; Sahel J; Korobelnik JF; Béchet S; Querques G; Souied EH
    Retina; 2018 Dec; 38(12):2285-2292. PubMed ID: 29190241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of aflibercept on exudative age-related macular degeneration in patients exhibiting complete ranibizumab resistance and tachyphylaxis.
    Gokce G; Durukan AH; Koylu MT; Kucukevcilioglu M
    Arq Bras Oftalmol; 2016; 79(6):384-389. PubMed ID: 28076566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real Life Data of Treat and Extend Intravitreal Ranibizumab and Aflibercept Therapy in Wet Age-related Macular Degeneration Patients: 3-Year Results.
    Ugurtay O; Kockar A; Sengul EA
    Korean J Ophthalmol; 2021 Aug; 35(4):280-286. PubMed ID: 34162188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
    Kim K; Kim ES; Kim Y; Yang JH; Yu SY; Kwak HW
    Retina; 2019 Feb; 39(2):303-313. PubMed ID: 29160779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seven-year outcome after 1-year fixed regimen of intravitreal aflibercept injections followed by pro re nata treatment for neovascular age-related macular degeneration.
    Hama Y; Miyata M; Ooto S; Tamura H; Ueda-Arakawa N; Muraoka Y; Miyake M; Takahashi A; Wakazono T; Uji A; Yamashiro K; Tsujikawa A
    Graefes Arch Clin Exp Ophthalmol; 2023 Jul; 261(7):1871-1881. PubMed ID: 36735070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of 12 Months Outcome of As-needed Intravitreal Aflibercept or Ranibizumab for the Treatment of Naïve Patients with Age-related Macular Degeneration].
    Umeda N; Hokao K; Tsukahara T; Okamura K; Uchio E
    Nippon Ganka Gakkai Zasshi; 2015 Dec; 119(12):839-45. PubMed ID: 26817131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Efficacy of Intravitreal Ranibizumab and Aflibercept in Eyes with Myopic Choroidal Neovascularization: 24-Month Follow-Up.
    Korol A; Kustryn T; Zadorozhnyy O; Pasyechnikova N; Kozak I
    J Ocul Pharmacol Ther; 2020 Mar; 36(2):122-125. PubMed ID: 31755809
    [No Abstract]   [Full Text] [Related]  

  • 32. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
    Inoue M; Arakawa A; Yamane S; Kadonosono K
    Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of the switch from intravitreal ranibizumab to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration: A 42-month retrospective real-world study.
    Ertan E; Efe N; Sabaner MC; Dogan M
    Niger J Clin Pract; 2021 Dec; 24(12):1824-1827. PubMed ID: 34889791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy.
    Ito A; Maruyama-Inoue M; Kitajima Y; Sato S; Inoue T; Yamane S; Kadonosono K
    PLoS One; 2020; 15(6):e0235213. PubMed ID: 32579608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab.
    Patel KH; Chow CC; Rathod R; Mieler WF; Lim JI; Ulanski LJ; Leiderman YI; Arun V; Chau FY
    Eye (Lond); 2013 May; 27(5):663-7; quiz 668. PubMed ID: 23558214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
    Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
    Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of Functional and Morphological Outcome after Aflibercept or Ranibizumab in Chronic Recurrent Neovascular Age-Related Macular Degeneration].
    Hoffmann AE; Maier M; Lohmann CP; Feucht N
    Klin Monbl Augenheilkd; 2016 Nov; 233(11):1260-1265. PubMed ID: 27130974
    [No Abstract]   [Full Text] [Related]  

  • 39. Intravitreal aflibercept in treatment-resistant pigment epithelial detachment.
    Kocak I
    Int Ophthalmol; 2017 Jun; 37(3):531-537. PubMed ID: 27444307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration.
    Broadhead GK; Hong T; Zhu M; Li H; Schlub TE; Wijeyakumar W; Chang AA
    Retina; 2015 May; 35(5):975-81. PubMed ID: 25627086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.